MiR-155 targeting FoxO3a regulates oral cancer cell proliferation,apoptosis,and DDP resistance through targeting FoxO3a

Abstract

This article has been retracted, and the online PDF replaced with this retraction notice.

Keywords

Oral cancer DDP resistance miR-155 FoxO3a

1. Introduction

Oral cancer (OC) is the most common malignant tumor in oral and maxillofacial region. Its incidence accounts for about 5% of systemic malignant tumors and 20% of head and neck malignant tumors [1]. Among the head and neck malignant tumors, the incidence of oral cancer ranks second only after nasopharyngeal carcinoma [2]. Although surgical resection, radiotherapy, chemotherapy, and other comprehensive treatments have been widely used in the treatment of oral cancer, the treatment effect is still unsatisfactory. The patient’s prognosis is poor and the survival rate is low.

FoxO3a is an important member of the forkhead transcription factor O subfamily (FoxO) and is a tumor suppressor gene [3, 4, 5]. As a transcription factor, FoxO3a can regulate the transcription and expression of various genes, thus affecting various biological processes, such as cell proliferation, cycle, apoptosis, migration, and invasion. Abnormal expression and dysfunction of Foxo3a is associated with tumor occurrence, progression, metastasis, and drug resistance [6, 7, 8].

MicroRNA is an endogenous non-coding small RNA molecule in eukaryotes that can be complementarily band to the 3’-untranslated region (3’-UTR) of the target gene mRNA, thus degrading mRNA or inhibiting mRNA translation to regulate the expression of target genes, thereby participating in the regulation of biological processes such as cell survival, proliferation, apoptosis, and migration. MicroRNA expression and dysfunction receive more and more attention in colon cancer [9], esophageal cancer [10], and breast cancer [11]. A number of studies showed that elevated expression of miR-155 is associated with the development, progression, and prognosis of oral cancer, suggesting that miR-155 acts as a pro-oncogene in oral cancer [12, 13, 14]. Bioinformatics analysis revealed a targeted complementary binding site between miR-155 and the 3’-UTR of FoxO3a mRNA. This study investigated whether miR-155 plays a role in regulating FoxO3a expression and affecting proliferation, apoptosis, and cisplatin (DDP) resistance in oral cancer cells.

2. Materials and methods

2.1 Main reagents and materials

Human normal oral epithelial cell line and special medium were purchased from Wuhan procell. Human oral cancer cell line KB was purchased from Shanghai Huiying Biotechnology. HEK293 T cells were purchased from Beijing Beina Biotechnology. DMEM medium was purchased from Hyclone. Opti-MEM and fetal Bovine serum (FBS) were purchased from Gibco. Trizol and Lipo 2000 transfection reagents were purchased from Thermo. ReverTra Ace qPCR RT Kit and SYBR dye were purchased from Toyobo. MiR-155 mimic, inhibitor, and miR-NC were purchased from RiboBio. Rrabbit anti-human polyclonal antibody Foxo3a antibody was purchased from Abcam. Rabbit anti-human polyclonal antibody $\beta$ -actin antibody, Annexin V/PI apoptosis detection kit, and CCK-8 cell activity detection reagent were purchased from Boster. Goat anti-rabbit HRP secondary antibody was purchased from Sangon. EdU cell proliferation assay reagent was purchased from Beyotime. Dual luciferase activity assay kit and pMIR carrier purchased from Promega. Cisplatin (DDP) was purchased from Sigma.

2.2 Cell culture

Human normal oral epithelial cell line was cultured in special medium (including M199, FBS, epithelial cell growth additive, Hydrocortisone, Insulin, Transferrin, Epinephrine, and penicillin-streptomycin). KB cells were cultured in DMEM medium containing 10% FBS and 1% penicillin-streptomycin. Both cells were cultured in a chamber containing 5% CO ${}_{2}$ at 37 ${}^{\circ}$ C. The cells were digested with 0.25% trypsin and passaged at a ratio of 1:4. Cells in the log phase were adopted for experiments.

2.3 DDP drug resistant cell line establishment

KB cells in logarithmic phase were treated by DDP from 0.1 $\mu$ g/mL for 2 weeks. Then cells kept growing and were treated by increased concentration of DDP up to 1.6 $\mu$ g/mL when the cells can stably grow in DDP. At last, the cells can be stable passaged in DDP to obtain DDP resistant KB/DDP cell line.

KB and KB/DDP cells were treated by different concentrations (0, 0.1, 1, 10, 100, and 1000 $\mu$ g/mL) of DDP for 48 h. Next, the cells were added with CCK-8 to measure the absorbance value (A450). Inhibition rate $=$ (1 $-$ A450 in drug group)/A450 in control $\times$ 100%. IC50 was calculated using SPSS software. Resistance index (RI) $=$ IC50 of drug resistant cell/IC50 of parent cell.

2.4 Dual luciferase reporter gene assay

The PCR product of the FoxO3a 3’-UTR full-length fragment or mutant fragment was double-digested and then ligated into the pMIR vector. After sequencing, the plasmid was designated as pMIR-FoxO3a-WT and pMIR-FoxO3a-MUT. The HEK293 T cells were transfected with pMIR-FoxO3a-WT (or pMIR-FoxO3a-MUT) together with miR-155 mimic (or miR-NC) by Lipofectamine 2000. After incubated for 48 h, luciferase activity was detected by Dual-Glo Luciferase Assay System kit according to the manual.

2.5 Cell transfection and grouping

KB/DDP cells were divided into miR-NC group and miR-155 inhibitor group. The cells were seeded in 6-well plate and treated by 1.6 $\mu$ g/mL DDP for 48 h. Next, the cells were tested on Beckmann FC500 MCL flow cytometry to evaluate cell apoptosis. The cells were digested and incubated in 10 $\mu$ M EdU for 2 h. Next, the cells were treated by 1.6 $\mu$ g/mL DDP for 48 h. Then the cell proliferation was determined by EdU staining kit according to the manual.

2.6 qRT-PCR

Trizol reagent was used to extract RNA and reverse transcribe RNA to cDNA. The reverse transcription system contained 1 $\mu$ g total RNA, 2 $\mu$ L RT Buffer (5 $\times$ ), 0.5 $\mu$ L oligo dT $+$ Random primer Mix, 0.5 $\mu$ L RT Enzyme Mix, 0.5 $\mu$ L RNase inhibitor, and RNase Free H2O. The reverse transcription was performed at 37 ${{}^{\circ}}$ C for 15 min and 98 ${{}^{\circ}}$ C for 5 min. The PCR reaction system was composed of 2 $\times$ SYBR Green Mixture 4.5 $\mu$ L, 2.5 $\mu$ m/L primers 1.0 $\mu$ L, cDNA 1 $\mu$ L, and ddH ${}_{2}$ O 3.0 $\mu$ L. The reaction was performed on Bio-Rad CFX96 at 95 ${{}^{\circ}}$ C for 5 min, followed by 40 cycles of 95 ${{}^{\circ}}$ C for 15 s and 60 ${{}^{\circ}}$ C for 1 min.

2.7 Western blot

Total protein was extracted from the cells by RIPA. After quantified by BCA method, a total of 40 $\mu$ g protein was separated by SDS-PAGE at 45 V for 150 min and transferred to PVDF membrane at 300 mA for 100 min. After blocked by 5% skim milk at room temperature, the membrane was incubated in primary antibody at 4 ${{}^{\circ}}$ C overnight (FoxO3a 1:800 and $\beta$ -actin 1:5000). After washed by PBST, the membrane was further incubated in HRP conjugated secondary antibody at room temperature for 60 min (1:10000). At last, the membrane was treated by BeyoECL Plus chemiluminiscence reagent and developed.

2.8 Cell apoptosis detection

The cells were digested by trypsin and collected. After resuspension in 100 $\mu$ l binding buffer, the cells were added with 5 $\mu$ l Annexin V-FITC and 5 $\mu$ l PI at room temperature avoid of light for 15 min. Then the cells were tested on flow cytometry.

2.9 Cell proliferation detection

The cells were added with EdU solution at 10 $\mu$ M in logarithmic phase. After incubation for 2 h, the cells were seeded for 48 h and digested by trypsin. After fixation in paraformaldehyde, the cells were incubated in 100 $\mu$ L TritonX-100 at room temperature and in 500 $\mu$ L reaction fluid at room temperature avoid of light for 30 min. At last, cells were tested on flow cytometry.

2.10 Statistical analysis

SPSS 18.0 software was applied for data analysis. Measurement data was presented as mean $\pm$ standard deviation and compared by $t$ test or one-way ANOVA. $P<$ 0.05 was depicted as significant difference.

3. Results

3.1 The targeted regulatory relationship between miR-155 and Foxo3a mRNA

Bioinformatics analysis showed the complementary binding site between miR-155 and the 3’-UTR of FoxO3a mRNA (Fig. 1A). Dual luciferase reporter gene assay exhibited that miR-155 mimic transfection significantly reduced the relative luciferase activity in HEK293 T cells transfected by pMIR-Foxo3a-WT but not by pMIR-FoxO3a-MUT, confirming that FoxO3a was the target gene of miR-155a (Fig. 1B).

Figure 1.

The targeted regulatory relationship between miR-155 and FoxO3a. (A) The complementary binding site between miR-155 and the 3’-UTR of FoxO3a mRNA. (B) Dual luciferase reporter assay. * $P<$ 0.05, compared with miR-NC.

3.2 KB/DDP cells exhibited strong proliferation and drug resistance

CCK-8 assay showed that the proliferative activities of parental KB cells were significantly lower than those of KB/DDP cells under the same dose treatment of DDP (Fig. 2). The IC ${}_{50}$ of KB cells was 2.66 $\pm$ 0.31 $\mu$ g/mL, while it was 33.46 $\pm$ 4.13 $\mu$ g/mL in the drug-resistant Caski/DDP cells, leading the RI of Caski/DDP cells at 12.57 (Table 1).

Table 1
RI comparison

Cell	IC50	RI
KB	2.66	12.57
KB/DDP	33.46

Figure 2.

CCK-8 detection of KB and KB/DDP cell viabilities. * $P<$ 0.05.

3.3 MiR-155 upregulated, while Foxo3a decreased in drug resistant cell

qRT-PCR demonstrated that compared with human normal oral epithelial cells, miR-155 expression was significantly elevated in KB cells, and its level was obviously higher in KB/DDP cells than that of parental KB cells (Fig. 3A). qRT-PCR revealed that the FoxO3a mRNA expression in KB cells was markedly lower than that of normal oral epithelial cells, and it was apparently lower in KB/DDP cells compared with the parental KB cells (Fig. 3A). Western blot exhibited that compared with normal oral epithelial cells, FoxO3a protein expression in KB cells was significantly downregulated, and its level in KB/DDP cells obviously attenuated (Fig. 3B).

Figure 3.

MiR-155 elevated, while FoxO3a downregulated in drug resistant cells. (A) qRT-PCR detection of miR-155 and FoxO3a expressions; (B) Western blot detection of Foxo3a protein expression; * $P<$ 0.05, compared with normal oral epithelial cells; # $P<$ 0.05, compared with KB cells.

3.4 MiR-155 inhibitor transfection promoted KB/DDP cell apoptosis and reduced DDP resistance

qRT-PCR showed that miR-155 inhibitor transfection significantly downregulated miR-155 expression and elevated Foxo3a mRNA level in KB/DDP cells compared with miR-NC group (Fig. 4A). Western blot demonstrated that miR-155 inhibitor transfection obviously elevated FoxO3a protein level in KB/DDP cells (Fig. 4B). Flow cytometry revealed that transfection of miR-155 inhibitor markedly enhanced cell apoptosis, while inhibiting cell proliferation in KB/DDP cells (Fig. 4C and D).

Figure 4.

MiR-155 inhibitor transfection promoted KB/DDP cell apoptosis and reduced DDP resistance. (A) qRT-PCR detection of miR-155 expression; (B) Western blot detection of FoxO3a protein expression; (C) Flow cytometry detection of cell apoptosis; (D) Flow cytometry detection of cell proliferation; * $P<$ 0.05, compared with miR-NC.

4. Discussion

In recent years, the incidence of oral cancer keeps increasing. About 300,000 oral cancer patients were diagnosed each year worldwide [15]. The incidence of oral cancer has ranked 9th, and the mortality rate ranks 8th in global malignant tumors. The pathogenesis of oral cancer is not fully understood, and is related to smoking, drinking, viral infection, eating habits, and other factors. Smoking and drinking are the biggest risk factors for oral cancer [16]. Although surgical resection, radiotherapy, chemotherapy and other comprehensive treatments have been widely used in the treatment of oral cancer, the treatment effect is still unsatisfactory. The patient’s prognosis is still poor, and the survival rate is low [17, 18, 19].

FoxO is a class of evolutionarily highly conserved transcription factors that are widely involved in the regulation of various biological processes, such as embryonic development, cell proliferation, cell cycle, and apoptosis. The FoxO transcription factor family contains four members, including FoxO1, FoxO3a, FoxO4, and FoxO6, of which FoxO3a is mostly investigated. FoxO3a is a well-defined tumor suppressor gene that regulates a variety of genes involved in cell proliferation, cell cycle, and apoptosis, such as BIM (Bcl-3 mediator of cell death, BIM), PUMA (p53 up-regulated modulator of apoptosis), CKI (cyclin-dependent kinase inhibitor), p27Kip1, and cyclin D1 (cyclin-dependent kinase D1). It participates in the regulation of multiple signaling pathways in tumor cells and various biological processes, such as proliferation, cycle, apoptosis, migration, and invasion [5, 20, 21, 22, 23, 24]. The abnormal expression and function of FoxO3a are related to the occurrence, progression, metastasis, and drug resistance of ovarian cancer [6], breast cancer [7], and lung cancer [8]. However, whether the abnormality of FoxO3a is related to the pathogenesis of oral cancer is unclear.

MiR-155 is a well-researched microRNA that is closely related to the occurrence and progression of various tumors, such as breast cancer [25], intestinal cancer [26], lung cancer [27]. It was shown that miR-155 overexpression is related to the occurrence, progression, and prognosis of oral cancer, suggesting that miR-155 plays an oncogene role in oral cancer [12, 13, 14]. Bioinformatics analysis revealed a targeted complementary binding site between miR-155 and FoxO3a. In this study, we explored whether miR-155 regulates the expression of FoxO3a and affects the proliferation and apoptosis of oral cancer cells.

In this study, the dual luciferase gene reporter assay demonstrated that transfection of miR-155 mimic significantly reduced the relative luciferase activity in pMIR-FoxO3a-wt transfected HEK293 T cells, but not in pMIR-FoxO3a-mut transfected HEK293 T cells, indicating that miR-155 can target the 3’-UTR region of FoxO3a mRNA and inhibit its expression. The CCK-8 assay showed that DDP treatment can significantly inhibit the proliferation of KB cells, but exhibited less effect on KB/DDP cells, indicating the successful establishment of DDP-resistant oral cancer cells. Compared with normal oral epithelial cells, miR-155 expression in oral cancer KB cells was significantly increased. Its level in drug-resistant oral cancer KB/DDP cells was obviously higher than that of parental KB cells. Compared with normal oral epithelial cells, FoxO3a expression in oral cancer KB cells was markedly reduced. Its level in drug-resistant oral cancer KB/DDP cells was apparently lower than that in parental oral cancer KB cells. This indicated that miR-155 plays a role in targeted inhibition of FoxO3a, and that increased expression of miR-155 and decreased expression of FoxO3a are related to the pathogenesis and DDP resistance of oral cancer cells.

This study further explored whether miR-155 plays a role in regulating the proliferation, apoptosis, and DDP resistance of oral cancer cells through FoxO3a. It was observed that the transfection of miR-155 inhibitor increased the expression of FoxO3a in KB/DDP cells, enhanced sensitivity to DDP, aggravated cell apoptosis under DDP treatment, and attenuated cell proliferative capacity. Bano et al. [28] found that the expression of miR-155 was significantly increased in oral cancer stem cells, and was related to the malignant biological characteristics of cancer stem cells. Baba et al. [13] showed that the expression of miR-155 was obviously upregulated in tumor tissues of patients with oral cancer, especially in metastatic tumor tissues. In oral cancer HSC-3 cells, transfection of miR-155 inhibitor markedly enhanced the expression of E-cadherin, inhibited EMT process, and attenuated the migration and metastasis of oral cancer cells. Kim et al. [12] revealed that the expression of miR-155 was apparently elevated in tumor tissues of patients with oral cancer, and was associated with tumor TNM stage and poor prognosis. Rather et al. [14] reported that the expression of miR-155 was significantly increased in oral cancer KB cell line and oral cancer patients. Overexpression of miR-155 in oral cancer KB cells obviously reduced CDC73 expression, promoted cell proliferation, and reduced cell apoptosis; inhibiting the expression of miR-155 markedly upregulated the expression of CDC73 in oral cancer cells, promoted cell apoptosis, inhibited cell proliferation, and reduced the tumorigenicity of KB cells in animals. This study combined the targeted regulation between miR-155 and FoxO3a, revealing that elevated expression of miR-155 plays a role in inhibiting FoxO3a expression, promoting oral cancer cell proliferation, reducing apoptosis, and enhanced DDP resistance. However, whether miR-155 regulates FoxO3a in relation to drug resistance in patients with oral cancer is still unclear.

5. Conclusion

Increased expression of miR-155 and decreased expression of FoxO3a were associated with DDP resistance in oral cancer cells. Inhibition of miR-155 expression upregulated FoxO3a expression, restrained oral cancer cell proliferation, promoted cell apoptosis, and enhanced DDP sensitivity in oral cancer cells.

References

Chang

J.T.

Hsieh

C.E.

and Lin

C.Y.

, The incidence of osteonecrosis in oral cavity cancer patients treated with radiation therapy, Int J Radiat Oncol Biol Phys 96(2S) (2016), e347.

Miller

Zhai

Habboush

J.Y.

Tzou

K.S.

Peterson

J.L.

Vallow

L.A.

Buskirk

S.J.

Patel

S.H.

and Foote

R.L.

, Prevalence and prognostic implication of human papillomavirus in oral cavity cancer, Int J Radiat Oncol Biol Phys 96(2S) (2016), e366.

Zhao

Xie

Dai

Zhao

Jiang

Deng

et al., CHP2 promotes cell proliferation in breast cancer via suppression of FOXO3a, Molecular Cancer Research: MCR 16(10) (2018), 1512–1522.

Chen

Xiao

Xiang

Yang

and Chen

, FOXO3a reverses the cisplatin resistance in ovarian cancer, Archives of Medical Research 49(2) (2018), 84–88.

Yang

Guan

Qian

Yao

Yin

and Zhao

, NVP-BKM120 inhibits colon cancer growth via foxO3a-dependent PUMA induction, Oncotarget 8(47) (2017), 83052–83062.

Chen

Xiao

Xiang

Yang

and Chen

, FOXO3a reverses the cisplatin resistance in ovarian cancer, Archives of Medical Research 49(2) (2018), 84–88.

Zhao

Xie

Dai

Zhao

Jiang

Deng

et al., CHP2 promotes cell proliferation in breast cancer via suppression of FOXO3a, Molecular Cancer Research: MCR 16(10) (2018), 1512–1522.

Gong

Cao

Yang

and Zeng

, Casticin suppresses the carcinogenesis of small cell lung cancer h446 cells through activation of AMPK/FoxO3a signaling, Oncology Reports 40(3) (2018), 1401–1410.

Huang

Tan

Huang

Chen

Lin

and Fu

S.W.

, MicroRNA biomarkers in colorectal cancer liver metastasis, Journal of Cancer 9(21) (2018), 3867–3873.

10.

H.B.

, MicroRNA-556-3p promotes the progression of esophageal cancer via targeting DAB2IP, European Review For Medical and Pharmacological Sciences 22(20) (2018), 6816–6823.

11.

Song

Y.K.

Wang

Wen

Y.Y.

Zhao

and Bian

Z.J.

, MicroRNA-22 suppresses breast cancer cell growth and increases paclitaxel sensitivity by targeting NRAS, Technology in Cancer Research & Treatment 17 (2018), 153303381880 9997.

12.

Kim

Yang

J.M.

Ahn

S.H.

Jeong

W.J.

Chung

J.H.

and Paik

J.H.

, Potential oncogenic role and prognostic implication of microRNA-155-5p in oral squamous cell carcinoma, Anticancer Research 38(9) (2018), 5193–5200.

13.

Baba

Hasegawa

Nagai

Uchida

Yamatoji

Kanno

N.I.

Yamagata

Sakai

Yanagawa

and Bukawa

, MicroRNA-155-5p is associated with oral squamous cell carcinoma metastasis and poor prognosis, Journal of Oral Pathology & Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 45(4) (2016), 248–255.

14.

Rather

M.I.

Nagashri

M.N.

Swamy

S.S.

Gopinath

K.S.

and Kumar

, Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: Implications for cancer therapeutics, The Journal of Biological Chemistry 288(1) (2013), 608–618.

15.

Torre

L.A.

Bray

Siegel

R.L.

Ferlay

Lortet-Tieulent

and Jemal

, Global cancer statistics 2012, CA: A Cancer Journal For Clinicians 65(2) (2015), 87–108.

16.

Kim

K.Y.

Zhang

Kim

S.M.

Lee

B.D.

and Cha

I.H.

, A combined prognostic factor for improved risk stratification of patients with oral cancer, Oral Diseases 23(1) (2017), 91–96.

17.

Cheraghlou

Schettino

Zogg

C.K.

and Judson

B.L.

, Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014, The Laryngoscope (2018).

18.

Webber

L.P.

Wagner

V.P.

Curra

Vargas

P.A.

Meurer

, Carrard

V.C.

Squarize

C.H.

Castilho

R.M.

and Martins

M.D.

, Hypoacetylation of acetyl-histone h3 (H3 K9ac) as marker of poor prognosis in oral cancer, Histopathology 71(2) (2017), 278–286.

19.

Tseng

W.T.

Chiang

W.F.

Liu

S.Y.

Roan

and Lin

C.N.

, The application of data mining techniques to oral cancer prognosis, Journal of Medical Systems 39(5) (2015), 59.

20.

Sun

Wang

Luo

Zhao

Zhang

Cui

Wang

et al., Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancer, International Journal of Clinical and Experimental Pathology 8(3) (2015), 2963–2970.

21.

Lin

Shen

Dan

Chen

Tanyi

J.L.

Montone

Fan

Huang

et al., RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/ FOXO3A/BIM axis in ovarian cancer cells, Signal Transduction and Targeted Therapy 3 (2018), 23.

22.

Lin

Ding

Jiang

and Li

, MEK inhibitors induce apoptosis via foxO3a-dependent PUMA induction in colorectal cancer cells, Oncogenesis 7(9) (2018), 67.

23.

Park

S.Y.

Piao

Thomas

Fuller

G.N.

and de Groot

J.F.

, Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma, Oncotarget 7(18) (2016), 26793–26805.

24.

Han

Zhao

Jiang

Liu

Wang

Jiang

and Wan

, Zinc deficiency impairs the renewal of hippocampal neural stem cells in adult rats: Involvement of foxO3a activation and downstream p27 (kip1) expression, Journal of Neurochemistry 134(5) (2015), 879–891.

25.

Zhang

Chen

C.J.

and Guo

G.L.

, MiR-155 promotes the proliferation and migration of breast cancer cells via targeting SOCS1 and MMP16, European Review For Medical and Pharmacological Sciences 22(21) (2018), 7323–7332.

26.

Khoshinani

H.M.

Afshar

Pashaki

A.S.

Mahdavinezhad

Nikzad

Najafi

Amini

Gholami

M.H.

Khoshghadam

and Saidijam

, Involvement of miR-155/ FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line, Japanese Journal of Radiology 35(11) (2017), 664–672.

27.

Lai

Chen

Liu

and Zhang

, MiR-155 mediates arsenic trioxide resistance by activating nrf2 and suppressing apoptosis in lung cancer cells, Scientific reports 7(1) (2017), 12155.

28.

Bano

Yadav

Mohania

and Das

B.C.

, The role of NF-kappaB and miRNA in oral cancer and cancer stem cells with or without HPV16 infection, PloS One 13(10) (2018), e0205518.

MiR-155 targeting FoxO3a regulates oral cancer cell proliferation,apoptosis,and DDP resistance through targeting FoxO3a

Abstract

Keywords

1. Introduction

2. Materials and methods

2.1 Main reagents and materials

2.2 Cell culture

2.3 DDP drug resistant cell line establishment

2.4 Dual luciferase reporter gene assay

2.5 Cell transfection and grouping

2.6 qRT-PCR

2.7 Western blot

2.8 Cell apoptosis detection

2.9 Cell proliferation detection

2.10 Statistical analysis

3. Results

3.1 The targeted regulatory relationship between miR-155 and Foxo3a mRNA

Table 1 RI comparison

5. Conclusion

References

Table 1
RI comparison